253 related articles for article (PubMed ID: 15995975)
1. Isolated central nervous system blast crisis in chronic myeloid leukemia.
Rajappa S; Uppin SG; Raghunadharao D; Rao IS; Surath A
Hematol Oncol; 2004 Dec; 22(4):179-81. PubMed ID: 15995975
[TBL] [Abstract][Full Text] [Related]
2. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid.
Bornhauser M; Jenke A; Freiberg-Richter J; Radke J; Schuler US; Mohr B; Ehninger G; Schleyer E
Ann Hematol; 2004 Jun; 83(6):401-2. PubMed ID: 14673623
[TBL] [Abstract][Full Text] [Related]
3. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
4. Imatinib mesylate (STI-571) given concurrently with nonmyeloablative stem cell transplantation did not compromise engraftment and resulted in cytogenetic remission in a patient with chronic myeloid leukemia in blast crisis.
Koh LP; Hwang WY; Chuah CT; Linn YC; Goh YT; Tan CH; Ng HJ; Tan PH
Bone Marrow Transplant; 2003 Feb; 31(4):305-8. PubMed ID: 12621468
[TBL] [Abstract][Full Text] [Related]
5. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
[TBL] [Abstract][Full Text] [Related]
6. Durable molecular response to imatinib mesylate following nonmyeloablative allogeneic stem-cell transplantation for persisting myeloid blast crisis in chronic myeloid leukemia.
Staber PB; Brezinschek R; Linkesch W; Sill H; Neumeister P
Haematologica; 2003 Aug; 88(8):ECR29. PubMed ID: 12935988
[TBL] [Abstract][Full Text] [Related]
7. Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
Colla S; Sammarelli G; Crugnola M; Ascani S; Sabbatini E; Bonomini S; Hojden M; Craviotto L; De Celis I; Morandi F; Caramatti C; Rizzoli V; Giuliani N
Eur J Haematol; 2004 May; 72(5):361-5. PubMed ID: 15059073
[TBL] [Abstract][Full Text] [Related]
8. Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib.
Fang B; Li N; Song Y; Han Q; Zhao RC
Ann Hematol; 2010 Nov; 89(11):1099-105. PubMed ID: 20499235
[TBL] [Abstract][Full Text] [Related]
9. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate.
Pfeifer H; Wassmann B; Hofmann WK; Komor M; Scheuring U; Brück P; Binckebanck A; Schleyer E; Gökbuget N; Wolff T; Lübbert M; Leimer L; Gschaidmeier H; Hoelzer D; Ottmann OG
Clin Cancer Res; 2003 Oct; 9(13):4674-81. PubMed ID: 14581336
[TBL] [Abstract][Full Text] [Related]
10. Isolated blast crisis in CNS in a patient with chronic myelogenous leukemia maintaining major cytogenetic response after imatinib.
Kim HJ; Jung CW; Kim K; Ahn JS; Kim WS; Park K; Ko YH; Kang WK; Park K
J Clin Oncol; 2006 Aug; 24(24):4028-9. PubMed ID: 16921058
[No Abstract] [Full Text] [Related]
11. Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with imatinib mesylate.
Matsuda M; Morita Y; Shimada T; Miyatake J; Hirase C; Tanaka M; Tatsumi Y; Maeda Y; Kanamaru A
Int J Hematol; 2005 May; 81(4):307-9. PubMed ID: 15914360
[TBL] [Abstract][Full Text] [Related]
12. Long-term remission with imatinib mesylate in Philadelphia chromosome-positive AML presenting as primary extramedullary myeloid sarcoma.
Ahmed MS; Kroft SH; Davis NB; King DM; Cheng YC
Leuk Res; 2008 Sep; 32(9):1476-9. PubMed ID: 18308388
[TBL] [Abstract][Full Text] [Related]
13. Imatinib activity in vitro in tumor cells from patients with chronic myeloid leukemia in chronic phase and blast crisis.
Olsson-Strömberg U; Aleskog A; Björnberg A; Höglund M; Simonsson B; Bengtsson M; Barbany G; Larsson R; Lindhagen E
Anticancer Drugs; 2006 Jul; 17(6):631-9. PubMed ID: 16917208
[TBL] [Abstract][Full Text] [Related]
14. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
Fujisawa S; Yano K; Kobayashi M
Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
[TBL] [Abstract][Full Text] [Related]
15. Promyelocytic blast crisis of chronic myeloid leukemia during imatinib treatment.
Chung HJ; Chi HS; Cho YU; Park CJ; Seo EJ; Kim KH; Lee JH
Ann Clin Lab Sci; 2008; 38(3):283-6. PubMed ID: 18715859
[TBL] [Abstract][Full Text] [Related]
16. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
Higashi T; Tsukada J; Kato C; Iwashige A; Mizobe T; Machida S; Morimoto H; Ogawa R; Toda Y; Tanaka Y
Am J Hematol; 2004 Jul; 76(3):275-8. PubMed ID: 15224366
[TBL] [Abstract][Full Text] [Related]
18. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
19. What is the best salvage therapy for treatment of isolated CNS relapse in elderly patients with imatinib-responsive Ph(+) ALL?
Mele G; Pinna S; Melpignano A; Romano A; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 Oct; 31(10):1445-7. PubMed ID: 17462730
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
